Form 4: HCA Healthcare Grants SARs to Chief Clinical Officer

HCA Healthcare's EVP and Chief Clinical Officer, Michael S. Cuffe, was granted 8,067 Stock Appreciation Rights with a strike price of $482.53.

Summary

• Michael S. Cuffe, Executive Vice President and Chief Clinical Officer of HCA Healthcare, Inc., was granted 8,067 Stock Appreciation Rights (SARs).
• The SARs have an exercise price of $482.53 per share.
• The grant date for these SARs was January 29, 2026.
• The SARs will vest in four equal annual installments, beginning on January 29, 2027.
• The expiration date for these Stock Appreciation Rights is January 29, 2036.
• Each SAR represents the right to receive the appreciation in value of one share of HCA Healthcare Common Stock.
• Following this transaction, Michael S. Cuffe beneficially owns 8,067 derivative securities (SARs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive alignment and retention strategies. It is not a major market-moving event but indicates ongoing commitment to executive performance.

Positives

• The grant of Stock Appreciation Rights aligns the executive's long-term financial interests with those of the shareholders, incentivizing stock price appreciation.
• This compensation structure serves as a retention tool for key management personnel like the EVP and Chief Clinical Officer.

Negatives

• The value of the SARs to the executive is entirely dependent on the future appreciation of HCA Healthcare's stock price above the exercise price of $482.53.
• There is no immediate cash benefit to the executive from this grant; value is realized only upon vesting and exercise.

Risks

• Market volatility could lead to HCA Healthcare's stock price not appreciating above the $482.53 exercise price, rendering the SARs worthless.
• Future changes in HCA Healthcare's operational performance or broader healthcare industry trends could negatively impact the stock price, diminishing the value of the SARs.

Future Outlook

The grant of Stock Appreciation Rights is a forward-looking incentive, designed to motivate the executive to contribute to the long-term growth and stock price appreciation of HCA Healthcare, with vesting scheduled over four years.

Industry Context

StockSavvy.ai notes that the grant of Stock Appreciation Rights is a common form of executive equity compensation in the healthcare industry and across publicly traded companies. It is used to align executive incentives with shareholder value creation without requiring an upfront capital outlay from the executive or immediate share issuance.

Comparison to Industry Standards

• Stock Appreciation Rights (SARs) are a standard component of executive compensation packages across various industries, including healthcare, comparable to grants seen at peers like Universal Health Services (UHS) or Tenet Healthcare (THC).
• The four-year vesting schedule is typical for long-term incentive plans, aiming to retain executives and encourage sustained performance, aligning with best practices for corporate governance and executive retention.

Stakeholder Impact

• Shareholders: The grant of SARs aims to align the interests of the EVP and Chief Clinical Officer with shareholders by incentivizing stock price growth.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• The Stock Appreciation Rights will begin to vest in four equal annual installments starting on January 29, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not contain new fundamental information that would alter an investment thesis for HCA Healthcare. The grant of Stock Appreciation Rights is a standard practice for executive incentive and retention, and while positive for alignment, it does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

HCA Healthcare, HCA, Stock Appreciation Rights, SARs, Executive Compensation, Form 4, Michael S. Cuffe, Equity Compensation